Supplemental material
Journal of Dermatological Treatment
Volume 33, 2022 - Issue 1
Related Research Data
Update of the EDEN Psoriasis Survey 2001-2006
Source:
Wiley
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study
Source:
Elsevier BV
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Source:
Elsevier BV
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Source:
American Academy of Dermatology, Inc. Published by Mosby, Inc.
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
Source:
Elsevier BV
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis.
Source:
Springer Science and Business Media LLC
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Source:
Massachusetts Medical Society
Ustekinumab in Japanese psoriasis patients
Source:
Wiley
Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year
Source:
Taylor & Francis
Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study.
Source:
Wiley
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Source:
Massachusetts Medical Society
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis
Source:
Elsevier BV
Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis:
Source:
SAGE Publications
Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis.
Source:
Academy of Managed Care Pharmacy
Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
Source:
Linköpings universitet, Avdelningen för hälso- och sjukvårdsanalys
Validity and reliability of patient reported outcomes used in Psoriasis: results from two randomized clinical trials
Source:
Springer Science and Business Media LLC
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Source:
Massachusetts Medical Society
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Source:
Massachusetts Medical Society
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
Source:
Massachusetts Medical Society
Pathogenesis and clinical features of psoriasis.
Source:
Elsevier BV
Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.
Source:
Academy of Managed Care Pharmacy
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
Source:
Elsevier BV
Linking provided by
